Company development history

1958

October 15 — plant commissioning date.
The first inoculation machine seeded, and the first kilograms of BIOMYCIN received by November 7.

1970

The USSR's first antibiotic drugs for veterinary use
Vitamin B12 obtained, the first antibiotic drugs in the USSR for veterinary use, growth stimulator for plants – gibberellin. Development and release of tablet-form drugs. Production facilities for manufacture of oxytetracycline, benzylpenicillin, phenoxymethylpenicillin were commissioned.

1980

Development of injectables production.
Production of plastic medical products was started. The plant was reorganized into the Kurgan medical preparations and articles plant Sintez. Manufacturing of new antifungal drugs — Amphotericin B, Amfogljukamin.

1990

Further development of production, introduction of new technologies.
The complex of local treatment facilities with mechanical and biological waste water treatment is commissioned, contaminated air emissions are eliminated. Production of ampicillin, heparin was started. The industrial complex is awarded with the order of Badge of Honor.

2000

Corporatization of enterprises occurred on December 30, 1992.
Changing the assortment policy. Search and development of finished dosage forms for the external and internal use made of generic drug substances (tablets, capsules, ampoules, ointments, tinctures, powders, eye drops). Their introduction increased the range from 40 to 200 titles.

2010

Manufacturing of modern, effective generic drugs, introduction of new pharmaceutical forms.
Started manufacturing of coated tablets, solutions for infusion in glass bottles and drops in polymer vials, powders in single-dose sachet type packs, sprays, gels. Production facilities were upgraded. Production of cephalosporin and penicillic substances were launched. Sintez is the only manufacturer who started production of sodium thiopental in Russia.

2018

Joined the Marathon Group investment holding. Company rebranding was completed.
Production of "polymeric containers for blood and its components with single-use solutions of CPD/SAGM, sterile "Gemasin", including with leukofilter, was started. The products have no domestic equivalents. Facilities for manufacturing of chemical and organic substances were commissioned. A workshop for the production of active pharmaceutical substances was created. Rebranding was conducted. In 2017, Sintez joined the Marathon Group investment holding (a sub-holding of Marathon Pharma).